Chat with a Mochi Medical provider
Cardiovascular disease and risk management: Standards of care in diabetes2024
Where can you find real Medvi reviews
Adding a GLP-1 receptor agonist or tirzepatide for adults with type 2 diabetes who are living with obesity, should be considered if: they have been taking initial therapy for at least 3 months and further medicines are needed to reach their individualised glycaemic targets and they are not already taking a GLP-1 receptor agonist or tirzepatide For adults with type 2 diabetes who are living with obesity who need further medicines to reach their individualised glycaemic targets and for whom a GLP-1 receptor agonist or tirzepatide is contraindicated, not tolerated, not appropriate or not effective: offer to add a DPP-4 inhibitor to their current treatment if this is contraindicated, not tolerated or not effective, offer to add: a sulfonylurea or pioglitazone or an insulin-based treatment (see the section on insulin-based treatments) For adults with type 2 diabetes who are living with obesity who need further medicines to reach their individualised glycaemic targets and are already taking a GLP-1 receptor agonist or tirzepatide, offer to add: a sulfonylurea or pioglitazone or an insulin-based treatment (see the section on insulin-based treatments) (6) Adults with chronic kidney disease If type 2 diabetes and an estimated glomerular filtration rate (eGFR) above 30 ml/min/1.73 m2: offer modified-release metformin and an SGLT-2 inhibitor
Ce systme enzymatique GSTM1 est sensible aux carences alimentaires (notamment la carence en cystine contenue principalement dans les oeufs), l'excs de graisses satures (notamment celles contenues dans les biscuits et charcuteries industrielles) et aux acides gras trans (notamment contenus dans les margarines, viennoiseries et biscuits industriels)
Diabetes 68 , 10621072 (2019)
